Weekly Docetaxel and Epirubicin in Treatment of Advanced Hormone-Refractory Prostate Cancer

Urology

Volumn 69, Issue 1, 2007, Pages 142-146

  Petrioli, Roberto ^a   Paolelli, Loretta ^a   Francini, Edoardo ^a   Manganelli, Antonio ^a   Salvestrini, Francesco ^a   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIRUBICIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; EPISTAXIS; FATIGUE; FEASIBILITY STUDY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT FAILURE;

EID: 33846515135     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.09.015     Document Type: Article

References (18)

1. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
2. Petrylak D.P., Tangen C.M., Hussain M.H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
3. Khan M.A., Carducci M.A., and Partin A.W. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 170 (2003) 1709-1716
4. Engels F.K., and Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 41 (2005) 1117-1126
5. Friedland D., Cohen J., Miller Jr. R., et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26 suppl 17 (1999) 19-23
6. Petrioli R., Pozzessere D., Messinese S., et al. Weekly low-dose docetaxel in hormone-resistant advanced prostate cancer patients previously exposed to chemotherapy. Oncology 64 (2003) 300-305
7. Francini G., Petrioli R., Manganelli A., et al. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 67 (1993) 1430-1436
8. Brausi M., Jones W.G., and Fossa S.D. High-dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC genitourinary group. Eur J Cancer 31A (1995) 1622-1626
9. Petrioli R., Fiaschi A.I., Pozzessere D., et al. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer 87 (2002) 720-725
10. World Health Organization: WHO criteria, in WHO Handbook for Reporting Results of Cancer Treatment. (Offset publication No. 48.) Geneva, World Health Organization, 1979.
11. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1 (1975) 277-299
12. Beer T.M., Pierce W.C., Lowe B.A., et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12 (2001) 1273-1279
13. Berry W., Dakhil S., Gregurich M.A., et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28 suppl 15 (2001) 8-15
14. Beer T.M., Eilers K.M., Garzotto M., et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21 (2003) 123-128
15. Dahut W.L., Gulley J.L., Arlen P.M., et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2532-2539
16. Pagani O., Sessa C., Nole F., et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 11 (2000) 985-991
17. Higano C.S., Ellis W., Russell K., et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48 (1996) 800-804
18. Beer T.M., Garzotto M., Henner W.D., et al. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 89 (2003) 968-970